Phosphorylated tau-targeting therapies (IMAGE)
Caption
Conventional small-molecule drugs for reducing pTau include phosphatase activators of PP2A, and kinase inhibitors of GSK3β, CDK5, etc., as well as active or passive immunotherapies targeting pTau. Following DEPTAC, a series of heterobifunctional targeting chimeras (TAC) for pTau including pTau-PROTAC, PhosTAC and AdPhosphatase system have been developed. These TACs can reduce pTau and hold potential for the treatment of tauopathies.
Credit
©Science China Press
Usage Restrictions
Use with credit.
License
Original content